Baisong Mei - 15 Oct 2026 Form 3 Insider Report for CITY THERAPEUTICS, INC. (CTY)

SEC form
3
Accepted by SEC
15 Oct 2026, 21:05:32 UTC
Prior SEC filing
05 Dec 2024
Source filing
View source filing
Filing notes and source

Key filing fact

Baisong Mei filed Form 3 for CITY THERAPEUTICS, INC. (CTY) on 15 Oct 2026.

Key facts

  • This page summarizes Baisong Mei's Form 3 filing for CITY THERAPEUTICS, INC. (CTY).
  • 0 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 15 Oct 2026, 21:05.

Change

  • Previous filing in this sequence was filed on 05 Dec 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001938499 Primary reporting owner

Mei Baisong

Relationship
Chief Medical Officer

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
228,743
Date
15 Oct 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTY holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
15 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
131,937
Exercise price
$1.84
Footnotes
F1
CTY holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
15 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
56,978
Exercise price
$5.36
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

25% of the shares underlying this option vested on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Footnote F2

The shares underlying this option vest in 48 equal monthly installments following June 3, 2026, subject to the Reporting Person's continued service on each such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .